Astria Therapeutics’ (ATXS) “Buy” Rating Reaffirmed at HC Wainwright
Astria Therapeutics (NASDAQ:ATXS – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 179.72% from the stock’s previous close. Other […]
Astria Therapeutics (NASDAQ:ATXS – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 179.72% from the stock’s previous close. Other […]
